Evaluating mFLUSIVA (mRNA Flu Vaccine): Regulatory Status, Molecular Dynamics, and Immunological Considerations

The authorization of mFLUSIVA (mRNA-1010, Moderna’s mRNA‑based seasonal influenza vaccine for adults 50+) marks the first influenza vaccine in synthetic messenger RNA platform.